CONMED Corporation (CNMD)

Over the past six months, CONMED's stock price has been influenced by several key events. The company's stock experienced a 52-week high of $74.70 and a low of $35.37. In Q3 2025, CONMED reported sales of $337.9 million, a 6.7% year-over-year increase, and authorized a $150.0 million share repurchase program while suspending the quarterly cash dividend. In Q4 2025, CONMED reported earnings that surpassed analyst expectations, but the stock fell 5.74% in after-hours trading. Management highlighted the company's decision to exit lower-growth gastroenterology product lines. There has been insider selling activity during this period.

According to CONMED's CFO, Todd Garner, the demand seasonality for the company's products and services is expected to align with typical patterns observed in the medtech industry, with no significant differences in selling days anticipated. Demand may follow general healthcare industry trends, which can sometimes see fluctuations based on factors like hospital budgeting cycles, elective procedure scheduling, and holiday periods.

CONMED Corporation is an American medical technology company specializing in the development, manufacture, and sale of surgical devices and equipment. Operating in the healthcare sector, its product portfolio includes orthopedic surgery and general surgery products. Key products include BioBrace, TruShot, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors for orthopedic surgery, and AirSeal systems, Buffalo Filter devices, and electrosurgical generators for general surgery. Founded in 1970, CONMED is headquartered in Largo, Florida.

CONMED Corporation has a significant international presence, selling its products in approximately 100 countries. The company maintains manufacturing facilities in the United States and Mexico. Its global sales and distribution efforts are coordinated through local country dealers, sub-distributors, sales agents, or direct in-country sales offices. CONMED has sales subsidiaries and branches in over 20 international locations, including countries across Europe, Australia, Latin America, Asia, North America, and the Middle East.

In the past year, CONMED's brand reputation has been shaped by its strategic focus on innovation and addressing operational challenges. CONMED has seen success with products like BioBrace and the launch of the PlumeSafe X5 smoke evacuation system. The company faced supply chain challenges, particularly within its Orthopedics product line, but backorder value and the number of SKUs on backorder were at a three-year low at the end of 2025. The decision to exit lower-growth gastroenterology product lines indicates a strategic effort to optimize its portfolio. Patrick J. Beyer became CONMED's President and CEO in January 2025. The suspension of quarterly cash dividends, while accompanied by a share repurchase program, could impact short-term sentiment.

CONMED Corporation's ownership is predominantly institutional, with institutional investors and index funds holding the vast majority of shares. As of September 2025, institutional ownership was around 111.7%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Earnest Partners Llc, Fuller & Thaler Asset Management, Inc., Westwood Holdings Group Inc, Bank Of America Corp /de/, Dimensional Fund Advisors Lp, State Street Corp, and Silvercrest Asset Management Group LLC. Individual insider ownership remains modest and is largely equity-award based.